JP Morgan Chase
SNDX icon

JP Morgan Chase’s Syndax Pharmaceuticals SNDX Stock Holding History

JP Morgan Chase’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-34,500
Closed -$456K – 7693
2024
Q4 		$456K Buy
34,500
+29,900
+650% +$512K ﹤0.01% 5090
2024
Q3 		$88.5K Hold
4,600
– – ﹤0.01% 5752
2024
Q2 		$94.4K Hold
4,600
– – ﹤0.01% 5540
2024
Q1 		$109K Buy
+4,600
New +$103K ﹤0.01% 5632
2020
Q3 		– Sell
-96,900
Closed -$1.44M – 5747
2020
Q2 		$1.44M Buy
+96,900
New +$1.48M ﹤0.01% 3313

Other funds holding SNDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

JP Morgan Chase's SNDX Position: Q1 2026 in Review

JP Morgan Chase reduced its Syndax Pharmaceuticals (SNDX) stake by 32% in Q1 2026, selling an estimated $2.61M and leaving 258,519 shares worth $5.81M. The position accounts for ﹤0.01% of the portfolio, ranked #3181.

JP Morgan Chase first reported a position in SNDX in Q2 2016 and has held it in 39 quarters since. The position peaked at $16.9M in Q4 2023. 246 funds tracked by Wall St. Rank hold SNDX as of Q1 2026.

  • JP Morgan Chase held 258,519 shares of Syndax Pharmaceuticals worth $5.81M as of Q1 2026.
  • JP Morgan Chase sold 119,985 Syndax Pharmaceuticals shares in Q1 2026, an estimated $2.61M.
  • Syndax Pharmaceuticals made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #3181 holding.
  • JP Morgan Chase first reported a position in Syndax Pharmaceuticals in Q2 2016 and has held it in 39 quarters since.
  • JP Morgan Chase's Syndax Pharmaceuticals position peaked at $16.9M in Q4 2023.
  • 246 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.